<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50531">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448381</url>
  </required_header>
  <id_info>
    <org_study_id>HPN-CTCL-01</org_study_id>
    <nct_id>NCT02448381</nct_id>
  </id_info>
  <brief_title>FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soligenix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soligenix</source>
  <brief_summary>
    <textblock>
      To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with
      patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response in 3 treated lesions as defined as a ≥50% improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) score when compared to patients receiving placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the ability of a 6-week course of SGX301 and visible light in patients with patch/plaque phase cutaneous T-cell lymphoma (CTCL, mycosis fungoides) to induce a treatment response in 3 lesions when compared to patients receiving placebo and visible light.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response in 3 treated lesions as defined to be a Composite Assessment of Index Lesion Disease Severity (CAILS) score of 0</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the ability of topical SGX301 and visible light in patients with patch/plaque phase CTCL to induce biopsy-proven Complete Response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Improvement of 3 treated lesions as measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) score</measure>
    <time_frame>16 weeks</time_frame>
    <description>To evaluate the degree of improvement of the lesions induced by topical SGX301 and visible light in patients with patch/plaque phase CTCL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response as measured monthly for 6 months by the appearance of new lesions after the treatment period has ended</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the duration of Partial and/or Complete Response in the lesions induced by topical SGX301 and visible light in patients with patch/plaque phase CTCL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Relapse as measured by any disease recurrence in participants with a Complete Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the time to lesion relapse induced by topical SGX301 and visible light in patients with patch/plaque phase CTCL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by the number of participants with Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>To assess the safety of topical SGX301 and visible light in patients with patch/plaque phase CTCL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cutaneous T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>SGX301</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.
Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.
Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.
Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGX301 (synthetic hypericin)</intervention_name>
    <description>0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.</description>
    <arm_group_label>SGX301</arm_group_label>
    <other_name>Hypericin</other_name>
    <other_name>Synthetic Hypericin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage
             IB, or Stage IIA.

          -  Subjects must have a minimum of three (3) evaluable, discrete lesions.

          -  Subjects must be willing to refrain from sunbathing for the duration of the study.

        Exclusion Criteria:

          -  History of sun hypersensitivity and photosensitive dermatoses including porphyria,
             systemic lupus erythematosus, Sjögren's syndrome, xeroderma pigmentosum, polymorphous
             light eruptions or radiation therapy within 30 days of enrolling.

          -  Pregnancy or mothers who are breast feeding.

          -  Males and females not willing to use effective contraception.

          -  Unhealed sunburn.

          -  Subjects receiving topical steroids or other topical treatments for CTCL within 2
             weeks.

          -  Subjects receiving systemic steroids, nitrogen mustard, psoralen UVA radiation
             therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other
             systemic therapies for CTCL within 3 weeks of enrollment.

          -  Subjects with significant history of systemic immunosuppression due to drugs or
             infection with HIV or HTLV 1.

          -  Subjects taking other investigational drugs or drugs of abuse within 30 days of entry
             into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Pullion, DO</last_name>
    <phone>609-538-8200</phone>
    <phone_ext>23</phone_ext>
    <email>cpullion@soligenix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard Straube, MD</last_name>
    <phone>609-538-8200</phone>
    <phone_ext>30</phone_ext>
    <email>rstraube@soligenix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Kaler</last_name>
      <email>dermresearch@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Bui</last_name>
      <email>dbui@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Cheung</last_name>
      <email>ccheung7@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Doyle</last_name>
      <email>bdoyle@therapeuticsresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Friebel</last_name>
      <email>jacquelyn.friebel@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kacie Carlson</last_name>
      <email>kacie.carlson@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lowe</last_name>
      <email>plowe@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Serrano</last_name>
      <email>linda.serrano@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danica Uzelac</last_name>
      <email>Danica_Uzelac@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Dermatology Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothy Craig</last_name>
      <email>DCraig2@ecommunity.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Tabacchi</last_name>
      <email>mtabacch@dom.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ressler</last_name>
      <email>Daniel.R.Ressler@hitchcock.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester Skin Lymphoma Medical Group</name>
      <address>
        <city>Fairport</city>
        <state>New York</state>
        <zip>14450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Poligone</last_name>
      <email>bpoligone@roclymphoma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erich Zirzow</last_name>
      <email>Erich.Zirzow@UHhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Leahy</last_name>
      <email>Deborah.Leahy@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue A. McCann</last_name>
      <email>mccannsa@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Bratcher</last_name>
      <email>nikki.bratcher@Vanderbilt.Edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Wilson</last_name>
      <email>clwilson@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lewis</last_name>
      <email>patricia@atxresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INOVA Schar Cancer Institute</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jeffords</last_name>
      <email>Kelly.Jeffords@inova.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Care Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hager Elgedawe</last_name>
      <email>helgedaw1@seattlecca.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Bock</last_name>
      <email>dbock@dermatology.wisc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rarediseases.org/</url>
    <description>The National Organization for Rare Disorders</description>
  </link>
  <link>
    <url>http://www.clfoundation.org/</url>
    <description>The Cutaneous Lymphoma Foundation</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>May 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTCL</keyword>
  <keyword>Mycosis fungoides</keyword>
  <keyword>Hypericin</keyword>
  <keyword>SGX301</keyword>
  <keyword>MF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypericin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
